# Effects of a NeuroAD System, for the Treatment of Alzheimer Disease

> **NCT02166827** · NA · TERMINATED · sponsor: **Neuronix Ltd** · enrollment: 1 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DEVICE:** NeuroAD
- **DEVICE:** Sham TMS+Cog

## Key facts

- **NCT ID:** NCT02166827
- **Lead sponsor:** Neuronix Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Administrative decision
- **Last updated:** 2017-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02166827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02166827, "Effects of a NeuroAD System, for the Treatment of Alzheimer Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02166827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*